Analysts Set Agenus Inc. (NASDAQ:AGEN) Price Target at $14.50

Shares of Agenus Inc. (NASDAQ:AGEN) have received an average recommendation of “Hold” from the five research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $14.50.

AGEN has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Agenus in a research report on Monday, December 29th. Wall Street Zen downgraded Agenus from a “buy” rating to a “hold” rating in a research report on Sunday.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in AGEN. Redwood Family Wealth LLC acquired a new stake in Agenus in the 4th quarter valued at $44,000. Ovata Capital Management Ltd acquired a new position in shares of Agenus during the 4th quarter worth about $97,000. Virtu Financial LLC bought a new position in shares of Agenus in the 4th quarter valued at about $108,000. EP Wealth Advisors LLC bought a new position in shares of Agenus in the 4th quarter valued at about $31,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of Agenus in the fourth quarter valued at about $54,000. Institutional investors own 61.46% of the company’s stock.

Agenus Stock Performance

AGEN stock opened at $3.39 on Friday. The stock has a 50-day moving average price of $3.21 and a two-hundred day moving average price of $3.72. The stock has a market cap of $130.18 million, a PE ratio of -7.37 and a beta of 1.56. Agenus has a 1 year low of $1.38 and a 1 year high of $7.34.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Monday, March 16th. The biotechnology company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $1.83. The firm had revenue of $34.20 million for the quarter, compared to the consensus estimate of $28.10 million. Agenus had a negative return on equity of 7.65% and a negative net margin of 2.67%. On average, analysts forecast that Agenus will post -12.55 earnings per share for the current fiscal year.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.